Senior Therapeutic Area Specialist Hematology - Western Saudi Arabia

Senior Therapeutic Area Specialist Hematology - Western Saudi Arabia

Senior Therapeutic Area Specialist (TAS)

100% Field base

Western Region of Saudi Arabia / Jeddah

The Senior TAS is responsible for the promotion of Stemline’s current and future products in hematology to both existing and potential customers. The goals of this position are to support patients with new innovations, increase market share by expanding business in current ecosystems, develop and encourage strong customer relationships, build brand loyalty, and to provide customer satisfaction.

It is a role with an extremely high level of autonomy, empowerment, visibility, and the unique chance to influence how Stemline is positioned in Saudi Arabia.

The advertised positions concerns the central & western regions in Saudi Arabia.

Responsibilities

• Identifies and defines key local prescriber groups relevant for Stemline's in-label products (segmentation / targeting), establishes and maintains professional relationships with these (potential) prescribers
• Collect & synthesize large volumes of clinical, medical & scientific insights by peer to peer business relationships with KEEs.
• Identify the customer patients’ journey gap and setting tactical plans to bridge it
• Scientific engagement and product relevant communication.
• Understand the business dynamics and build key accounts mapping capabilities.
• Working on developing patient journey per account to address the drivers and barriers for the formulary inclusion and increase patients access
• IMS data analysis to ensure reaching to the full potential as well as identifying any new opportunities.
• Working closely with the planners, purchasers and buyers to ensure delivering our value to the patients.
• CFT Collaboration to provide the most comprehensive solutions for different stakeholders
• Address the value driven to the Ecosystem community
• Ensures full compliance in all customer engagement efforts according to Stemline's SOPs as well as local laws and regulations

Skills / Knowledge

The Menarini Group is present in 140 countries worldwide with over 17,500 employees. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history. Founded in 1886 in Naples under the name of Farmacia Internazionale, in 1915 Menarini moved to Florence where the Group’s headquarters are located still today.

More recently Menarini has made a commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and / or solid tumors, and through the acquisition of Stemline Therapeutics in June 2020, Menarini strengthened its oncology portfolio with the addition of both commercial and clinical-stage assets. These assets include ELZONRIS® (tagraxofusp), a targeted therapy directed to the IL-3R (CD123), approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of adult and pediatric patients, with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). In Europe, in January 2021 ELZONRIS® was approved by the EMA as monotherapy for the first-line treatment of adult patients with BPDCN.

The acquisition of Stemline established Menarini’s presence in the US biopharmaceutical oncology market, where the company will support further development of Stemline’s assets and will enable global expansion by leveraging its commercial infrastructure in Europe and other ex-US geographies.

Menarini also entered into a global license agreement with Radius Health to complete the development of Orserdu (Elacestrant,) an oral SERD in late stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study Menarini-Stemline is commercializing Orserdu in US, Europe and AsiaPac. Most recently Menarini secured their entry into an exclusive licensing agreement with Karyopharm whereby Menarini also commercializes NEXPOVIO, Karyopharm’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in Europe and other key global territories. NEXPOVIO has been approved by EMA in 2021 for the treatment of relapsed / refractory Multiple Myeloma and marketed in Germany in 2022 for the first time.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

#J-18808-Ljbffr